Last reviewed · How we verify
FP-020
At a glance
| Generic name | FP-020 |
|---|---|
| Sponsor | Foresee Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) (PHASE2)
- Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FP-020 CI brief — competitive landscape report
- FP-020 updates RSS · CI watch RSS
- Foresee Pharmaceuticals Co., Ltd. portfolio CI